|Bid||44.50 x 1300|
|Ask||45.49 x 800|
|Day's Range||44.40 - 45.27|
|52 Week Range||31.56 - 45.27|
|Beta (5Y Monthly)||0.78|
|PE Ratio (TTM)||58.56|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
One of the most attractive reasons to invest in health-care stocks continues to be the world's aging population.The United Nations says people age 65 and older are the fastest-growing age group worldwide. It estimates that by 2050, one out of every six people will be 65 or older, accounting for 16% of the planet's total population, up from 9% in 2011. That figure is even larger in Europe and North America, where the U.N. predicts the number will be closer to 25%. The demand for health-care products and services should only increase as a result.Yes, health-care stocks will be coming off a weak 2019. Through mid-November, the S&P; 500 was sitting on nearly 25% gains, while the sector had improved by roughly half that. They'll also have to contend with uncertainty regarding the future of health care as the 2020 presidential election approaches. But don't sleep on the space in the year ahead.For one, health-care stocks tend to outperform during periods of economic weakness. For instance, the Health Care Select Sector SPDR Fund (XLV) delivered a 39.6% total loss (share price plus dividends) during the 2007-09 bear market - more than 15 percentage points better than the S&P; 500\. Thus, headlines warning of an economic slowdown or even a recession in 2020 actually bode well for the sector.Also, health care has traded at a price-to-earnings ratio more expensive than the overall market more often than not over the past 20 years. However, according to the Charles Schwab Center for Research, the sector's P/E currently is cheaper than the S&P; 500, providing a better buying opportunity.Here, then, are the 13 best health-care stocks to buy for 2020, including a couple of funds for investors who want to diversify. SEE ALSO: Every Warren Buffett Stock Ranked: The Berkshire Hathaway Portfolio
This week's military contracting roundup features three contract notices for food distribution, staffing of certified registered nurse anesthetists and neurostimulator implantable devices, as well as solicitations for four contracts at Joint Base San Antonio.
Does the December share price for Boston Scientific Corporation (NYSE:BSX) reflect what it's really worth? Today, we...
The drug makers and medical device firms that made the most payments to District physicians and health systems last year include a handful of industry giants with deep local ties.
While the market driven by short-term sentiment influenced by the accomodative interest rate environment in the US, increasing oil prices and deteriorating expectations towards the resolution of the trade war with China, many smart money investors kept their cautious approach regarding the current bull run in the third quarter and hedging or reducing many of […]
Boston Scientific (BSX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Many patients with severe but stable heart disease who routinely undergo invasive procedures to clear and prop open clogged arteries would do as well by just taking medications and making lifestyle changes, U.S. researchers reported on Saturday. The $100 million government-backed study, presented at the American Heart Association (AHA) meeting in Philadelphia, is the largest yet to look at whether procedures to restore normal blood flow in patients with stable heart disease offers an added benefit over more conservative treatment with aspirin, cholesterol-lowering drugs and other measures. At least two prior studies determined that artery-clearing and stenting or bypass surgery in addition to medical treatment does not significantly lower the risk of heart attacks or death compared with non-invasive medical approaches alone.
Boston Scientific Corporation (NYSE: BSX) are up 8.5% since the company reported third-quarter earnings in late October. At 10:10 a.m., a trader sold 1,656 Boston Scientific call options with a $33 strike price expiring on Jan. 17, 2020 at the bid price of 64.1 cents. At 10:12 a.m., a trader bought 620 Boston Scientific call options with a $42.50 strike price expiring on Nov. 29 near the ask price at 40.9 cents.
One of the best investments we can make is in our own knowledge and skill set. With that in mind, this article will...
Firms have a variety of reasons for forgoing dividends. But some say Berkshire Hathaway, Facebook, and others have the means and should initiate dividends.
Moody's Investors Service ("Moody's") assigned a Baa2 rating to the new senior unsecured notes offering of Boston Scientific Corporation ("Boston Scientific"). There are no changes to Moody's existing ratings of Boston Scientific including the Baa2 senior unsecured long-term rating and the Prime-2 short-term rating. Moody's views the transaction as a credit positive as it will lower Boston Scientific's interest expense.
Third-quarter EPS season is in the homestretch, with blue-chip Utilities, Financial Services, Consumer and Industrial companies all releasing reports. Through 11/1/2019, Refinitiv reported that 356 S&P 500 companies have now announced 3Q earnings, with 76% coming in above consensus, ahead of the past four-quarters average percentage of 74%. The better-than-expected results have improved the overall forecast for the quarter to a -0.8%, from -3.2% at the start of the reporting season. Our analysts are always on the lookout for companies that raise their outlooks during earnings season. Management’s ability to “raise guidance” can often be a catalyst to strong returns in the quarters ahead. Following are 12 BUY-rated companies in Argus coverage for which management has raised guidance during the current EPS reporting season.
Shares of Boston Scientific and Thermo Fisher Scientific neared breakouts Wednesday after the medical technology firms topped third-quarter earnings and revenue expectations from analysts.
Relief that Boeing Co. kept a key timeline for its grounded 737 Max jet boost shares of the airplane maker and was a spot of good news on a mixed day for earnings that included a quarterly miss for Caterpillar Inc.
Shares of the medical-device company jumped nearly 5% early Wednesday after its third-quarter earnings results exceeded expectations and it slightly increased its full-year guidance.
Boston Scientific (BSX) is making an all-out effort to solidify its core businesses and invest in the new technologies as well as the global markets. This reflects on the sales uptick in Q3.
The company raises its full-year adjusted earnings outlook to between $1.55 and $1.58 a share, up from $1.54 and $1.58.
Boston Scientific (BSX) delivered earnings and revenue surprises of 2.63% and 2.36%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Shares of Boston Scientific Corp. rallied 3.5% in premarket trading Wednesday, after the medical technology company reported third-quarter earnings that rose above expectations, and lifted its full-year outlook. Net income fell to $126 million, or 9 cents a share, from $432 million, or 31 cents a share, in the year-ago period. Excluding non-recurring items, such as acquisition-related charges, adjusted earnings per share grew to 39 cents from 35 cents, above the FactSet consensus of 38 cents. Sales rose 13.1% to $2.71 billion, beating the FactSet consensus of $2.65 billion, as MedSurg sales increased 13.2%, Cardiovascular sales grew 11.3% and Rhythm and Neuro sales rose 5.4%. The company expects adjusted fourth-quarter EPS of 42 cents to 45 cents, surrounding the FactSet consensus of 44 cents, and raised its 2019 guidance range to $1.55 to $1.58 from $1.54 to $1.58. The stock has lost 11% over the past three months through Tuesday, while the S&P 500 has slipped 0.3%.